Day: Day 1: 2026

Sponsored by

As precision medicine reshapes healthcare, the U.S. Food and Drug Administration plays a critical role in translating scientific innovation into safe, effective, and accessible patient care. This session will explore how regulatory frameworks are evolving to keep pace with advances in genomics, biomarkers, and targeted therapies. Panelists will discuss accelerated approvals, real-world evidence, evolving standards […]

Following the 2026 mid-term elections, what will dominate the policy conversations related to personalized medicine? Panelists will discuss potential implications for areas critical to supporting personalized medicine research, adoption, coverage, and reimbursement. INTRODUCER | Mike Ybarra, M.D., Chief Medical Officer, PhRMA PANELIST | Rachel Sher, J.D., MPH, Partner, Manatt, Phelps & Phillips, LLP PANELIST | Priscilla VanderVeer, Executive […]

Advances in blood-based diagnostic testing are transforming how diseases can be identified, even years before symptoms emerge. Yet while the scientific promise of early detection and management of diseases has accelerated rapidly, widespread adoption across healthcare systems remains uneven. This panel discussion will bring together leaders from diagnostics, clinical medicine, health systems, payer organizations, policy, […]

This joint keynote discussion will explore how advances in biomarker testing, diagnostics, and targeted treatments are converging to reshape Alzheimer’s disease. These advances highlight neurology as an increasingly important sector of the personalized medicine landscape. The conversation will consider what is required to translate scientific progress into meaningful patient impact, including the importance of accessible […]

PRESENTER | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus AWARDEE | Norman E. Sharpless, M.D., Professor of Cancer Policy and Innovation, University of North Carolina School of Medicine; 15th Director of the National Cancer Institute (2017-2022) and Former Acting Commissioner of the U.S. Food and Drug Administration (2019)

Sponsored by

This session will explore how emerging AI technologies are transforming drug discovery and development through clinical care – from de novo drug design and target identification to clinical trial design and preventive care. Looking ahead to 2050, panelists will examine whether technologies such as AI, computational diagnostics, and digital health tools will accelerate R&D and […]